Publications by authors named "Gabriel J Robbie"

Claim this Profile
P
Platform Assessment of Concentration-QTc Relationship Across GalNAc-siRNA Molecules.
Prajakta Badri, Kiranmai Kolachana, Anh Duong, Maxwell Lasko, Tirtha Nandi, Gabriel J Robbie

Clin Pharmacokinet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation.
Prajakta Badri, Bahru Habtemariam, Megan Melch, Valerie A Clausen, Seth Arum, Gabriel J Robbie

Clin Pharmacokinet· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.
Akshay S Desai, David J Webb, Jorg Taubel, Sarah Casey, Yansong Cheng, Gabriel J Robbie

N Engl J Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria.
Jongtae Lee, Megan Melch, Gabriel J Robbie

CPT Pharmacometrics Syst Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of oxalate by novel LC-MS/MS: assay development, validation and application in lumasiran clinical trials.
Valerie A Clausen, Karen H Cao, John M Gansner, Gabriel J Robbie, Jing-Tao Wu

Bioanalysis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria.
Megan Melch, Jongtae Lee, Claudia Jomphe, Gabriel J Robbie

Clin Pharmacokinet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Prajakta Badri, Xuemin Jiang, Anna Borodovsky, Nader Najafan, Jae Kim, Gabriel J Robbie

Clin Pharmacokinet· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection.
Sneha V Gupta, Marie C Fanget, Christopher MacLauchlin, Valerie A Clausen, Jing Li, Gabriel J Robbie

Drugs R D· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Daphne Vassiliou, Eliane Sardh, Pauline Harper, Amy R Simon, Valerie A Clausen, Gabriel J Robbie

Clin Pharmacol Ther· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria.
Prajakta Badri, Xuemin Jiang, Anna Borodovsky, Nader Najafian, Jae Kim, Gabriel J Robbie

Clin Pharmacokinet· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Bahru A Habtemariam, Verena Karsten, Husain Attarwala, Varun Goel, Megan Melch, Gabriel J Robbie

Clin Pharmacol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normal reference ranges for urinary δ-aminolevulinic acid and porphobilinogen levels.
Sagar Agarwal, Bahru Habtemarium, Yuanxin Xu, Amy R Simon, Jae B Kim, Gabriel J Robbie

JIMD Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Sagar Agarwal, Amy R Simon, Varun Goel, Bahru A Habtemariam, Valerie A Clausen, Gabriel J Robbie

Clin Pharmacol Ther· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic-Pharmacodynamic Model of Serum Transthyretin Following Patisiran Administration.
Varun Goel, Nathalie H Gosselin, Claudia Jomphe, Xiaoping Zhang, Jean-Francois Marier, Gabriel J Robbie

Nucleic Acid Ther· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Xiaoping Zhang, Varun Goel, Gabriel J Robbie

J Clin Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Xiaoping Zhang, Varun Goel, Husain Attarwala, Marianne T Sweetser, Valerie A Clausen, Gabriel J Robbie

J Clin Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy Adults.
Xiang-Qing Yu, Gabriel J Robbie, Yuling Wu, Mark T Esser, Kathryn Jensen

Antimicrob Agents Chemother· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.
Warren Greth, Gabriel J Robbie, Philip Brohawn, Micki Hultquist, Bing Yao

Immunotherapy· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Dose Escalation Study of MEDI-565, a Bispecific T-Cell Engager that Targets Human Carcinoembryonic Antigen, in Patients With Advanced Gastrointestinal Adenocarcinomas.
Michael Pishvaian, Michael A Morse, Jennifer McDevitt, Jonathan D Norton, Song Ren, Gabriel J Robbie

Clin Colorectal Cancer· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
Bo Zheng, Xiang-Qing Yu, Warren Greth, Gabriel J Robbie

Br J Clin Pharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Michael L Forbes, Veena R Kumar, Ram Yogev, Xionghua Wu, Gabriel J Robbie

Hum Vaccin Immunother· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.
Gabriel J Robbie, Doris Makari, Brian Harris, Genevieve A Losonsky, Hasan S Jafri

Infect Dis Ther· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
William V La Via, Gerard F Notario, Xiang-Qing Yu, Shringi Sharma, Peter A Noertersheuser, Gabriel J Robbie

Pulm Pharmacol Ther· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults.
Gabriel J Robbie, Ryan Criste, William F Dall'acqua, Kathryn Jensen, Nita K Patel

Antimicrob Agents Chemother· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Rajesh Narwal, Lorin K Roskos, Gabriel J Robbie

Clin Pharmacokinet· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis